DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM ...

H.C. Wainwright analyst Ed Arce keeps a Neutral rating on Durect (DRRX) without a price target after the company announced that data from the ...

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Durect (DRRX – Research Report) today. The company’s shares opened today at ...

Durect (DRRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one ...

StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX – Free Report) in a research note issued to investors on Tuesday. The firm issued a sell rating on the specialty pharmaceutical ...

After Nektar’s mauling it was Durect’s turn to face the panel with its POSIMIR (bupivacaine extended-release solution), an investigational post-operative pain relief depot product. Posimir is ...

U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling around 80 points on Wednesday The Dow traded down 0.23% to 34,074.30 while the NASDAQ fell 0.01% to 13,638.07.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Durect (DRRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...